Drug Trial Radar · NCT05334277
Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA
Last checked: Nov 20, 2026Latest source record: Aug 31, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
280
Planned (sponsor's estimate)
Start
May 6, 2022
Primary completion
Feb 28, 2025
Study completion Feb 29, 2028
Sponsor
- Lead sponsor
- Sun Yat-sen UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Allist Pharmaceuticals, Inc.; GeneCast Biotechnology Co., Ltd.
- First posted
- Apr 19, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
EGFR mutation positive advanced NSCLC patients with uncleared ctDNA have poor prognosis, whether they can benefit from combination therapy has not been reported. This study aims to investigate the efficacy and safety of combination therapy compared with furmonertinib monotherapy in advanced EGFR mutant NSCLC with uncleared circulating tumor cell DNA.
Conditions
- Non-small Cell Lung Cancer
Interventions
FurmonertinibDrug
Furmonertinib 80mg QD
FurmonertinibDrug
Furmonertinib 80mg QD
Furmonertinib/Pemetrexed/CarboplatinDrug
Furmonertinib 80mg daily + Pemetrexed (500 mg/m2) plus carboplatin (AUC 5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by pemetrexed maintenance (500 mg/m2) every 3 weeks.
Furmonertinib/Pemetrexed/Carboplatin/BevacizumabDrug
Furmonertinib 80mg daily + Pemetrexed (500 mg/m2) plus carboplatin (AUC 5) plus bevacizumab (7.5mg/kg) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by pemetrexed (500 mg/m2) with bevacizumab (7.5mg/kg) maintenance every 3 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS)Time frame: The primary analysis of Progression-free survival (PFS) based on investigator assessment will occur when PFS maturity is observed at approximately 34 months after the first patient begin study treatment
Locations
26 sites in 1 country. Site status is shown where the registry gives one.
The First Hospital of Jilin University
Changchun, China · Not yet recruiting
Sichuan Provincial People's Hospital
Chengdu, China · Not yet recruiting
Dongguan People's Hospital
Dongguan, China · Not yet recruiting
Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang People's hospital
Dongyang, China · Not yet recruiting
The First People's Hospital of Foshan
Foshan, China · Not yet recruiting
Affiliated Cancer Hospital and Institute of Guangzhou Medical University
Guangzhou, China · Not yet recruiting
Nanfang Hospital, Southern Medical University
Guangzhou, China · Not yet recruiting
Sun Yat-sen University cancer center
Guangzhou, China · Recruiting
The First Affiliated Hospital, Sun Yat-sen University
Guangzhou, China · Not yet recruiting
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, China · Not yet recruiting
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, China · Not yet recruiting
Zhejiang Provincial Hospital of Chinese Medicine
Hangzhou, China · Not yet recruiting
Jiangmen Central Hospital, Affiliated Jiangmen Hospital of Sun Yat-sen University
Jiangmen, China · Not yet recruiting
Affiliated Jinhua Hospital, Zhejiang University School of Medicine
Jinhua, China · Not yet recruiting
Mianyang Central Hospital
Mianyang, China · Not yet recruiting
The First Affiliated Hospital of Nanchang University
Nanchang, China · Not yet recruiting
Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute
Shenyang, China · Not yet recruiting
Shijiazhuang People's hospital
Shijiazhuang, China · Not yet recruiting
The Affiliated Cancer Hospital of Xinjiang Medical University
Ürümqi, China · Not yet recruiting
The Third Affiliated Hospital of Wenzhou Medical University, Rui'an People's Hospital
Wenzhou, China · Not yet recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China · Not yet recruiting
Yijishan Hospital, Wannan Medical College
Wuhu, China · Not yet recruiting
Tangdu Hospital, Fourth Military Medical University
Xi'an, China · Not yet recruiting
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, China · Not yet recruiting
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, China · Not yet recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.